DMAA Enters LOI for $1.0B De-SPAC with Power Analytics Global Corp.

summarizeSummary

Drugs Made In America Acquisition Corp. has signed a non-binding Letter of Intent to merge with Power Analytics Global Corp. in a de-SPAC transaction, valuing the target at approximately $1.0 billion.

check_boxKey Events

• LOI Signed for De-SPAC Transaction

  Drugs Made In America Acquisition Corp. entered into a non-binding Letter of Intent with Power Analytics Global Corp. for a de-SPAC business combination.

• Target Valuation Set at $1.0 Billion

  The proposed transaction anticipates an implied equity valuation of approximately $1.0 billion for Power Analytics Global Corp., subject to adjustments.

• Minimum Cash Condition Expected

  The definitive business combination agreement is expected to include a minimum cash condition in the range of $25 million to $50 million.

• Potential for Additional Financing

  The parties may pursue additional financing, including PIPE investments, to support the transaction.

auto_awesomeAnalysis

Drugs Made In America Acquisition Corp. (DMAA) has taken a significant step towards completing its business combination by entering into a Letter of Intent (LOI) for a de-SPAC transaction with Power Analytics Global Corp. This LOI, which anticipates valuing the target at approximately $1.0 billion, is a crucial development for the SPAC, fulfilling its primary mandate. This follows recent efforts by DMAA to secure financing and extend its deadline to complete a business combination, indicating progress towards a definitive agreement. While the LOI is non-binding and subject to further negotiation and due diligence, it signals a clear path forward for the company, especially as its stock trades near its 52-week high.